(Total Views: 50)
Posted On: 04/25/2025 5:07:23 PM
Post# of 92
NetworkNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Featured in Benzinga Video Highlighting 75% HyBryte™ Response Rate in FDA-Backed Skin Cancer Trial
Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on rare diseases, is featured in a new Benzinga video detailing clinical progress for its lead candidate HyBryte™, which achieved a 75% response rate in a trial for cutaneous T-cell lymphoma (CTCL), a rare form of skin cancer. The trial is supported by funding from a U.S. Food and Drug Administration’s Orphan Products Development Grant and showcases HyBryte’s™ potential as a first-in-class, light-activated, non-invasive therapy.
HyBryte™ is a first-in-class photodynamic therapy activated by safe visible light and has previously received Orphan Drug and Fast Track designations. Soligenix plans to continue advancing regulatory discussions as it positions HyBryte™ for potential commercialization.
For more information, visit the company’s website at https://www.soligenix.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on rare diseases, is featured in a new Benzinga video detailing clinical progress for its lead candidate HyBryte™, which achieved a 75% response rate in a trial for cutaneous T-cell lymphoma (CTCL), a rare form of skin cancer. The trial is supported by funding from a U.S. Food and Drug Administration’s Orphan Products Development Grant and showcases HyBryte’s™ potential as a first-in-class, light-activated, non-invasive therapy.
HyBryte™ is a first-in-class photodynamic therapy activated by safe visible light and has previously received Orphan Drug and Fast Track designations. Soligenix plans to continue advancing regulatory discussions as it positions HyBryte™ for potential commercialization.
For more information, visit the company’s website at https://www.soligenix.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
(0)
(0)Scroll down for more posts ▼
